Omega‐3 and hemocompatibility‐related adverse events

Hemocompatibility‐related clinical adverse events (HRAEs) are major causes of readmission in patients with left ventricular assist devices (LVADs). Omega‐3 is an unsaturated fatty acid that possesses anti‐inflammatory and antiangiogenic properties. We aimed to investigate the impact of omega‐3 therapy on HRAEs during LVAD support.

[1]  T. Imamura,et al.  Optimal haemodynamics during left ventricular assist device support are associated with reduced haemocompatibility‐related adverse events , 2019, European journal of heart failure.

[2]  G. Giridharan,et al.  Evaluation of flow-modulation approaches in ventricular assist devices using an in-vitro endothelial cell culture model. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  M. Mehra.  The burden of haemocompatibility with left ventricular assist systems: a complex weave. , 2019, European heart journal.

[4]  D. Burkhoff,et al.  Omega-3 Therapy Is Associated With Reduced Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device , 2018, Circulation. Heart failure.

[5]  M. Mehra,et al.  Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM 1 study. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  D. Burkhoff,et al.  Optimal Hemodynamics During LVAD Support Are Associated With Reduced Readmission Rate , 2018 .

[7]  T. Imamura,et al.  Neurohormonal Blockade Reduces Adverse Events During LVAD Support , 2018 .

[8]  Jouke Dijkstra,et al.  Detection of early changes in the coronary artery microstructure after heart transplantation: A prospective optical coherence tomography study. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  V. Jeevanandam,et al.  Tumor necrosis factor-α levels and non-surgical bleeding in continuous-flow left ventricular assist devices. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  G. Ewald,et al.  Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure , 2017, Circulation.

[11]  D. Farrar,et al.  Outcomes in HeartMate II Patients With No Antiplatelet Therapy: 2-Year Results From the European TRACE Study. , 2017, The Annals of thoracic surgery.

[12]  Gregory A. Ewald,et al.  A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure , 2017, The New England journal of medicine.

[13]  N. Uriel,et al.  PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  Snehal R. Patel,et al.  Association of Nasal Mucosal Vascular Alterations, Gastrointestinal Arteriovenous Malformations, and Bleeding in Patients With Continuous-Flow Left Ventricular Assist Devices. , 2016, JACC. Heart failure.

[15]  Gene Kim,et al.  Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding , 2016, Circulation.

[16]  Jessica L. Howard,et al.  HeartMate II Left Ventricular Assist Device Geometry on Chest Radiograph Does Not Correlate with Risk of Pump Thrombosis , 2015, ASAIO journal.

[17]  F. Kallel,et al.  Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  E. Novak,et al.  Pre-Operative Right Ventricular Dysfunction Is Associated With Gastrointestinal Bleeding in Patients Supported With Continuous-Flow Left Ventricular Assist Devices. , 2015, JACC. Heart failure.

[19]  D. Panigrahy,et al.  ω-3 polyunsaturated fatty acids-derived lipid metabolites on angiogenesis, inflammation and cancer. , 2014, Prostaglandins & other lipid mediators.

[20]  G. Stevens,et al.  Readmissions after ventricular assist device: etiologies, patterns, and days out of hospital. , 2013, The Annals of thoracic surgery.

[21]  Nader Moazami,et al.  The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[22]  N. Kalupahana,et al.  Health benefits of n-3 polyunsaturated fatty acids: eicosapentaenoic acid and docosahexaenoic acid. , 2012, Advances in food and nutrition research.

[23]  Z. Demirozu,et al.  Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  Kortaro Tanaka,et al.  Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients: Subanalysis of the JELIS Trial , 2008, Stroke.

[25]  H. Kawano,et al.  Effects of highly purified ethyl all-cis-5,8,11,14,17-icosapentaenoate (EPA-E) on rabbit platelets. , 1993, Biological & pharmaceutical bulletin.